Toyota quietly settles Saylor case, abandons co-defendant dealership
September 23, 2010
Personal Injury
Toyota Motor Corp. has reached a settlement with the families of Mark Saylor and his wife and brother-in-law over the high-profile crash near San Diego last year that killed all the occupants of a rented Lexus ES 350, including the ... Read More
FDA puts tight restrictions on Avandia due to heart attack, stroke risk
September 23, 2010
Pharmaceutical
The Food and Drug Administration (FDA) voted today not to remove the Type 2 diabetes drug Avandia from the market, despite studies that indicate the medication puts users at an elevated risk for cardiovascular events, such as heart attack and ... Read More
Scores of NYC bus drivers engaged in distracting activities while driving
September 23, 2010
Personal Injury
New York Metropolitan Transit Authority (MAT) drivers received a startling number of distracted driving citations so far this year, according to Department of Transportation officials. ... Read More
Government to study physical and psychological harm of BP oil spill
September 23, 2010
Environmental
Working with teams of doctors, scientists, and public health experts, the Department of Health and Human Services (HHS) is currently planning and developing a large-scale study of the short-term and long-term physical and psychological tolls the BP oil spill has ... Read More
Documentary aims to show the ‘real’ face of epilepsy
September 23, 2010
Pharmaceutical
Do you have an amazing story to share with the world about epilepsy? If so, you can apply to be chosen as one of the “faces” of epilepsy in a documentary designed to create awareness and to educate others about ... Read More
DePuy hip replacement recall may affect wide range of patients
September 23, 2010
Pharmaceutical
It used to be that the average patient for a hip replacement surgery was between 65 and 80 years old. The surgery, first performed in 1960, is a major undertaking, involving one of the body’s largest weight-bearing joints. However, advances ... Read More
Panel rejects diet drug based on modest results, possible cancer risk
September 23, 2010
Product Liability
A Food and Drug Administration (FDA) advisory panel voted to reject Arena Pharmaceuticals’ new diet drug, Lorcaserin, because its showed only modest weight loss results in study participants and raised concerns of possible cancer risk. The FDA isn’t required to ... Read More